Development and Production of membrane Proximal External Region (MPER)/ Anti-HIV broadly neutralizing antibodies (bNAbs) for prevention, therapy or cure

针对多个中和表位的长半衰期bNAb的生产和临床测试将提高bNAb用于预防、治疗和治愈策略的覆盖率和可能的成功率。VRC需要开发和生产针对除CD 4结合位点以外的表位的bNAb，以最终与CD 4 bs bNAb联合收割机组合用于预防和治疗。这一领域的进展将广泛影响以下战略：1）预防HIV-1感染的母亲向新生儿和母乳喂养的婴儿传播; 2）预防通过性传播感染HIV; 3）对HIV-1感染者的治疗应用（包括消除潜在的储存库）。 最近，多个研究小组已经鉴定和表征了针对MPER和HIV包膜的其他中和位点的新型广泛中和抗体。VRC将开发MPER mAb并将其单独或作为组合方法的一部分进入临床。

Production and clinical testing of long half-life bNAbs targeting multiple neutralizing epitopes will improve the coverage and likely success of bNAbs for prophylaxis, therapy, and cure strategies. The VRC requires development and production of a bNAbs directed against an epitope other than CD4 binding site to ultimately combine with a CD4bs bNAb for prevention and treatment. Advances in this area will broadly impact strategies for: 1) prevention of transmission from HIV-1 infected mothers to newborn and breastfeeding infants; 2) prevention of HIV infection by sexual transmission; and 3) therapeutic application in HIV-1 infected individuals (including elimination of the latent reservoir). In the recent past, multiple research groups have identified and characterized novel broadly neutralizing antibodies directed against the MPER and other neutralization sites of HIV envelope. The VRC will development MPER mAbs and move them into the clinic, either alone or as part of combination approaches.